Novel Sjogren's Drug Passes First Phase III Test

Novel Sjogren's Drug Passes First Phase III Test

(MedPage Today) -- ORLANDO -- An investigational CD40L antagonist called dazodalibep looks to be nearing the finish line on the way to approval for Sjögren's disease, based on results from a 48-week phase III trial reported here. With scores...

How Amgen, In A Buy Zone, Is Taking On Novartis With A First-Ever

Amgen unveiled test results Wednesday that suggest it could have one of the first immune-modulating treatments for Sjogren's disease.

Amgen's Sjogren's drug cuts disease activity in trial

AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE - PressReach

Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren’s Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced results from the Phase 3 OASIZ-301 study of dazodalibep, the only global Phase 3 trial to demonstrate clinically meaningful improvements in systemic … Continue reading "AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS F…

Amgen Announces Positive Phase 3 Results for Sjögren’s Drug

The results came from the OASIZ-301 study of dazodalibep. Amgen plans to present the full findings at ACR Convergence 2026.

Amgen Inc. (AMGN) Stock: Phase 3 Drug Success Sparks Hope for New Sjögren’s Treatment

TLDR Amgen (AMGN) stock falls 0.77% despite promising Phase 3 dazodalibep trial results. Amgen’s Phase 3 trial meets primary endpoints, offering hope for Sjögren’s patients. Dazodalibep significantly reduces systemic disease activity after 48 weeks of use. Amgen’s experimental drug improves dryness symptoms in patients with Sjögren’s. Amgen reports balanced serious adverse events as its Phase 3 drug program advances. Amgen has reported positive…